192 related articles for article (PubMed ID: 12540202)
1. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.
Haga JH; Jennings LK; Slack SM
Ann Biomed Eng; 2002; 30(10):1262-72. PubMed ID: 12540202
[TBL] [Abstract][Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
3. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M; Bertram U; Peter K; Bode C; Ruef J
J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
[TBL] [Abstract][Full Text] [Related]
4. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
5. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
6. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
[TBL] [Abstract][Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
8. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
[TBL] [Abstract][Full Text] [Related]
9. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
Frelinger AL; Furman MI; Barnard MR; Krueger LA; Dae MW; Michelson AD
Am J Cardiol; 2003 Nov; 92(9):1099-101. PubMed ID: 14583364
[TBL] [Abstract][Full Text] [Related]
11. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
Kleiman NS
Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
[No Abstract] [Full Text] [Related]
13. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
Schrör K
Herz; 2001 Apr; 26 Suppl 1():30-5. PubMed ID: 11349624
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
15. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
[TBL] [Abstract][Full Text] [Related]
16. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
17. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
18. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
19. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
Caron A; Théorêt JF; Mousa SA; Merhi Y
J Cardiovasc Pharmacol; 2002 Aug; 40(2):296-306. PubMed ID: 12131559
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
